© 2018 Miraculo Inc. All Rights Reserved
Cannabinoids are a group of chemicals naturally occurring cannabis plant (cannabis sativa). Cannabidiol (CBD) is one of these chemicals and studies have suggest that it has anti inflammatory effects when induced in animals. Tetrahydrocannabinol (THC) is another one of these compounds that wields a psychotropic effect in animals. Cannabinoid receptors (CB1 and CB2) are found in the endocannabinoid system and allow endogenous cannabinoids to bind and do their job in the body. This paper will look at the endocannabinoids systems role in mediating anxiety disorders and what cannabinoids can do to reduce the symptoms of this disorder.
Here is the full scientific article if you wish to download it.
Endocannabinoid system, a target for psychiatric disorder treatment?
Medicinal chemistry has made small-molecule agents with drug-like character that strongly and safely change the action of the subtle endocannabinoid system compounds as potential treatments for psychiatric disorders. Two cannabinoid receptors CB1 and CB2 now represent main endocannabinoid-system therapeutic targets for cannabinoids. Two endocannabinoid deactivating enzymes, fatty acid amide hydrolase (FAAH) and soluble monoacylglycerol lipase (MGL), are becoming more popular targets for inhibitors that indirectly make endocannabinoid-system signalling stronger. Continued profiling of possible selective cannabinoids in relevant disease models, identification of additional cannabinoid-related therapeutic targets, and validation of new pharmacological modes of endocannabinoid system modulation will undoubtedly invite further translational efforts in the cannabinoid field for treating psychiatric disorders and other medical conditions.
Cannabinoids have a therapeutic potential
In preclinical models, endocannabinoid system alterers exert therapeutically relevant impacts on biological and behavioural endpoints related to neurobiological/psychiatric working.
Novel pharmacological modalities will be increasingly applied to the endocannabinoid system for potential therapeutic benefit with improved safety. Emerging targets, e.g. diacylglycerol lipase, and metabolites, e.g. endocannabinoid-derived oxidation products including prostaglandin ethanolamides, will be studied for potential therapeutic relevance.